Finance

Beta
Lists
003090:KRX
Daewoong Co Ltd
₩18,520.00
+2.60%
(+470.00) 1D
Jun 12, 12:05:23 PM GMT+9  ·   KRW
All symbols
SymbolPriceChange% Change
Generating top insights for 003090...
Open
₩18,250
High
₩18,790
Low
₩18,110
Mkt. cap
1.08T
Avg. vol.
71.81K
Volume
25.29K
Dividend
1.08%
Quarterly dividend
₩50
Ex-dividend date
Dec 27, 2024
P/E ratio
4.13
52-wk high
₩30,600
52-wk low
₩16,230
EPS
₩4,480
Shares outstanding
58.14M
No. of employees
379
Open
₩18,250
High
₩18,790
Low
₩18,110
Mkt. cap
1.08T
Avg. vol.
71.81K
Volume
25.29K
Dividend
1.08%
Quarterly dividend
₩50
Ex-dividend date
Dec 27, 2024
P/E ratio
4.13
52-wk high
₩30,600
52-wk low
₩16,230
EPS
₩4,480
Shares outstanding
58.14M
No. of employees
379
News stories
From sources across the web
About Daewoong Co Ltd
CEO-
Employees379
FoundedAug 15, 1945
Headquarters-
SectorPharmaceutical industry
Websitedaewoong.com
Previous reportsAll values in KRW
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in KRW
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
528.43B
542.18B
516.33B
492.71B
Cost of goods sold
234.78B
253.36B
253.72B
233.39B
Cost of revenue
234.78B
253.36B
253.72B
233.39B
Research and development expenses
46.89B
45.27B
50.47B
47.71B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
156.58B
156.79B
171.85B
156.35B
Operating expense
208.31B
208.27B
229.10B
211.53B
Total operating expenses
443.09B
461.63B
482.83B
444.93B
Operating income
85.33B
80.54B
33.51B
47.78B
Other non operating income
-18.35B
-488.77M
4.85B
-4.18B
EBT including unusual items
69.24B
80.05B
49.71B
67.90B
EBT excluding unusual items
69.37B
80.05B
68.33B
45.80B
Income tax expense
7.90B
17.40B
-19.69B
14.64B
Effective tax rate
11.41%
21.73%
-39.60%
21.56%
Other operating expenses
1.45B
2.22B
1.60B
2.62B
Net income
38.88B
40.13B
69.88B
35.26B
Net profit margin
7.36%
7.40%
13.53%
7.16%
Earnings per share
-
-
-
-
Interest and investment income
1.53B
-
1.86B
1.71B
Interest expense
-3.44B
-
-3.98B
-3.13B
Net interest expenses
-1.91B
-
-2.13B
-1.42B
Depreciation and amortization charges
1.67B
2.41B
1.38B
1.12B
EBITDA
99.72B
95.81B
51.09B
68.08B
Gain or loss from assets sale
-21.46M
-14.78M
-39.74B
56.20M
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer